Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 93-100

  Hudis, Clifford ^a   Seidman, A ^a   Baselga, J ^a   Raptis, G ^a   Lebwohl, D ^a   Gilewski, T ^a   Moynahan, M ^a   Sklarin, N ^a   Fennelly, D ^a   Crown, J P A ^a   Surbone, A ^a   Uhlenhopp, M ^a   Riedel, E ^a   Yao, T J ^a   Norton, L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; AMENORRHEA; ARTICLE; BLOOD TOXICITY; BONE PAIN; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DYSPHAGIA; DYSPNEA; EDEMA; FATIGUE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0032919709     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.93     Document Type: Article

References (35)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339:1-15, 71-85, 1992
2. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989
3. Misset J, Palma M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145, 1996
4. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. J Clin Oncol 14:35-45, 1996
5. Carpenter JT, Velez-Garcia E, Aron BS, et al: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (adriamycin), and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: A Southeastern Cancer Study Group study. Proc Am Soc Clin Oncol 13:66, 1994 (abstr 68)
6. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
7. Skipper H, Schabel FJ, Wilcox W: Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1, 1964 (abstr)
8. Law L: Origin of resistance of leukaemic cells to folic acid antagonists. Nature 169:628, 1952 (abstr)
9. Goldie J, Coldman A: Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 70:127-131, 1986
10. Luria S, Delbruck M: Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491, 1943 (abstr)
11. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
12. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988
13. Surbone A, Gilewski T, Norton L: Cytokinetics, in: Holland JF, Bast RC Jr, Morton DL, et al (eds): Cancer Medicine, Vol 1 (ed 4). Baltimore, MD, Williams & Wilkins, 1996, pp 769-798
14. Bonadonna G, Zambette M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273:542-547, 1995
15. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
16. Crown J, Kritz A, Vahdat L, et al: Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 11:1144-1149, 1993
17. Wood W, Budman D, Korzun A, et al: Dose and dose intensity trial of adjuvant chemotherapy for stage II. node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
18. Bronchud MH, Howell A, Crowther D, et al: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121-125, 1989
19. Seidman A, Reichman B, Crown J, et al: Taxol plus recombinant human granulocyte colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: A preliminary report. J Natl Cancer Inst Monogr 15:171-175, 1993
20. Lichtman S, Ratain M, Van Echo D, et al: Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: A Cancer and Leukemia Group B study. J Natl Cancer Inst 85:1319-1326, 1993
21. Hudis C, Lebwohl D, Crown J, et al: Dose-intensive sequential crossover adjuvant chemotherapy for women with high risk node-positive primary breast cancer, in: Salmon SE (ed): Adjuvant Therapy of Cancer IV. Philadelphia, PA, JB Lippincott, 1993, pp 214-219
22. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Hudis C, Seidman A, Baselga J, et al: Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22:18-23, 1995 (suppl 15)
24. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three axillary lymph nodes. J Clin Oncol 9:2134-2140, 1991
25. Hussein A, Plumer M, Vredenburgh J, et al: High-dose chemotherapy (HDC) with cyclophosphamide (C) cisplatin (P), and BCNU (B) (CPB) and autologous bone marrow (ABM) and peripheral blood progenitor cells (PBPCs) for stage II/III breast cancer involving 4-9 axillary lymph nodes. Proc Am Soc Clin Oncol 15:A1026, 1996
26. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
27. Henderson I, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390a)
28. DeCillis A, Anderson S, Bryant J, et al: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: An update. Proc Am Soc Clin Oncol 16:130a, 1997 (abstr)
29. Fisher B, Anderson S, Wickerham D, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
30. Nabholtz J-M, Gelman K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
31. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 388)
32. Seidman A, Hochhauser D, Gollub M, et al: Ninety-six- hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
33. Holmes F, Valero V, Walter R, et al: Phase III trial of paclitaxel administered over 3- or 96-hours for metastatic breast cancer. Proc Am Soc Clin Oncol 15:106, 1996 (abstr 91)
34. Mamounas E, Brown A, Smith R, et al: Effect of taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3- to 24-hr infusion of high-dose taxol. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 389)
35. Wolmark N, Fisher B, Anderson S. The effect of increasing dose intensity and cumulative dose of adjuvant cyclophosphamide in node positive breast cancer: Results of NSABP B-25. Breast Cancer Res Treat 46:26, 1997 (abstr)